[8-K] agilon health, inc. Reports Material Event

Rhea-AI Filing Summary

agilon health, inc. furnished an update on its latest performance. On November 4, 2025, the company provided a press release detailing financial results for the three and nine months ended September 30, 2025, and shared an investor presentation.

The materials were furnished, not filed, under Items 2.02 and 7.01, which limits their use under certain Exchange Act provisions. The press release appears as Exhibit 99.1 and the investor presentation as Exhibit 99.2.

0001831097FALSE00018310972025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________________________________________

FORM 8-K

_____________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

_____________________________________________

agilon health, inc.

(Exact name of Registrant as Specified in Its Charter)

_____________________________________________

Delaware

001-40332

37-1915147

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

440 Polaris Parkway, Suite 550

Westerville, Ohio

43082

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 562 256-3800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_____________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.01 per share

AGL

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2025, agilon health, inc. (the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 7.01 Regulation FD Disclosure.

On November 4, 2025, the Company issued an investor presentation regarding the Company’s financial results for the three and nine months ended September 30, 2025. A copy of the investor presentation is furnished herewith as Exhibit 99.3.

The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K and the related information in Exhibits 99.1 and 99.2 attached hereto is being furnished herewith, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing with, the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference therein.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit Number						Description
99.1						Press Release dated November 4, 2025.
99.2						Investor Presentation dated November 4, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

									agilon health, inc.
Date:			November 4, 2025			By:			/s/ JEFFREY SCHWANEKE
									Jeffrey Schwaneke Chief Financial Officer

FAQ

What did AGL disclose in this 8-K?

The company furnished a press release and an investor presentation covering financial results for the three and nine months ended September 30, 2025.

Which exhibits were included with AGL's filing?

Exhibit 99.1 is the press release dated November 4, 2025, and Exhibit 99.2 is the investor presentation dated November 4, 2025.

Are the materials considered filed with the SEC?

No. The information in Items 2.02 and 7.01 and related exhibits was furnished, not filed, and is not subject to Section 18 liabilities.

What period do the results cover for AGL (AGL)?

The results cover the three and nine months ended September 30, 2025.

What is AGL’s trading symbol and exchange?

AGL common stock trades on the New York Stock Exchange under the symbol AGL.

When was the earliest event reported?

The earliest event reported was on November 4, 2025.